Compare Bristol-Myers Squibb Co (BMY) vs Chipotle Mexican Grill, Inc. (CMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Chipotle Mexican Grill, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $63.86 (market cap $129.94B), while Chipotle Mexican Grill, Inc. trades at $32.78 (market cap $40.49B). The key difference: Bristol-Myers Squibb Co is far larger — about 3.2× Chipotle Mexican Grill, Inc.'s market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Chipotle Mexican Grill, Inc. pays none. Which is the better fit depends on your goals.
| BMY | CMG | |
|---|---|---|
Market Cap | $129.94B | $40.49B |
Sector | Health | Consumer Cyclical |
52-Week High | $65.89 | $44.04 |
52-Week Low | $42.60 | $28.17 |
Enterprise Value | $163.92B | $45.24B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Chipotle Mexican Grill (CMG) trades at $32.25, up 0.34% on the day, amid a bearish technical signal despite recent earnings beats. The stock faces headwinds from a recent salmonella outbreak linked to jalapeños, contributing to a 12.64% weekly drop. Fundamentally, revenue growth remains robust, reaching $11.93B in 2025, with strong profitability metrics including a 49.56% ROE. Analyst consensus is overwhelmingly bullish with a $42.17 price target, though technical indicators show selling pressure with key support at $32.
The outlook for CMG balances strong fundamentals against near-term operational risks. Wall Street's buy ratings (70.15%) reflect confidence in long-term growth, but recent food safety issues and declining net income margins pose immediate challenges. Investors should weigh the company's consistent revenue trajectory against potential volatility from ongoing outbreaks and rising costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Chipotle Mexican Grill, Inc.
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →
